Inhibitory effect of the combination therapy of simvastatin and pinocembrin on atherosclerosis in apoE-deficient mice

Lipids in Health and Disease

Volumn 11, Issue 1, 2012, Pages

  Sang, Hui ^a   Yuan, Na ^a   Yao, Shutong ^a   Li, Furong ^a   Wang, Jiafu ^a   Fang, Yongqi ^a   Qin, Shucun ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Apolipoprotein E knockout mice; Atherosclerotic lesion; Combined therapy; Pinocembrin; Simvastatin

Indexed keywords

APOLIPOPROTEIN E; ENDOTHELIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; NITRIC OXIDE; PINOCEMBRINE; SIMVASTATIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; VASCULOTROPIN; FLAVANONE DERIVATIVE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; AORTA VALVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ATHEROSCLEROSIS; BLOOD; DIET THERAPY; DRUG COMBINATION; GENETICS; HUMAN; LIPID DIET; METABOLISM;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; DIET, HIGH-FAT; DRUG COMBINATIONS; ENDOTHELINS; FLAVANONES; HUMANS; LIPIDS; MALONDIALDEHYDE; MICE; NITRIC OXIDE; SIMVASTATIN; SUPEROXIDE DISMUTASE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MLCS; MLOWN;

EID: 84870375736     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-166     Document Type: Article

References (27)

1. Davidson MH: Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors. Am J Manag Care. 2007, 13 (Suppl 10): S260-S269.
2. Giannotti G, Landmesser U: Endothelial dysfunction as an early sign of atherosclerosis. Herz. 2007, 32: 568-572. 10.1007/s00059-007-3073-1
3. Hirase T, Node K: Endothelial dysfunction as a cellular mechanism for vascular failure. Am J Physiol Heart Circ Physiol. 2012, 302 (3): H499-H505. 10.1152/ajpheart.00325.2011
4. Inoue T, Node K: Vascular failure: a new clinical entity for vascular disease. J Hypertens. 2006, 24 (11): 2121-2130. 10.1097/01.hjh.0000249684.76296.4f
5. Yang HJ, Choi MJ, Wen H, Kwon HN, Jung KH, Hong SW, Kim JM, Hong SS, Park S: An effective assessment of simvastatin-induced toxicity with NMR-based Metabonomics approach. PLoS One. 2011, 6 (2): e16641- 10.1371/journal.pone.0016641
6. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P: The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008, 102 (10 Suppl): 1K-34K.
7. Dujovne CA, Williams CD, Ito MK: What combination therapy with a Statin, if any, would you recommend?. Curr Atheroscler Rep. 2011, 13 (1): 12-22. 10.1007/s11883-010-0150-3
8. Sforcin JM, Bankova V: Propolis: is there a potential for the development of new drugs?. J Ethnopharmacol. 2011, 133 (2): 253-260. 10.1016/j.jep.2010.10.032
9. Gardana C, Scaglianti M, Pietta P, Simonetti P: Analysis of the polyphenolic fraction of propolis from different sources by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2007, 45 (3): 390-399. 10.1016/j.jpba.2007.06.022
10. Zhu XM, Fang LH, Li YJ, Du GH: Endothelium-dependentand-independent relaxation induced by pinocembrin in rat aortic rings. Vascul Pharmacol. 2007, 46 (3): 160-165. 10.1016/j.vph.2006.09.003
11. Volpi N, Bergonzini G: Analysis of flavonoids from propolis by on-line HPLC-electrospray mass spectrometry. J Pharm Biomed Anal. 2006, 42 (3): 354-361. 10.1016/j.jpba.2006.04.017
12. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A, Sunagawa K: Bone marrow-Derived Monocyte Chemoattractant Protein-1 Receptor CCR2 Is Critical in Angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004, 24 (11): e174-e178. 10.1161/01.ATV.0000143384.69170.2d
13. Song G, Liu J, Zhao Z, Yu Y, Tian H, Yao S, Li G, Qin S: Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE- knockout mice fed high-fat diet. Lipids Health Dis. 2011, 10: 8- 10.1186/1476-511X-10-8
14. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, Rosa R, Hermanowski-Vosatka A, Wang PR, Zhang D, Peterson L, Detmers PA, Chao YS, Wright SD: Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 2001, 21 (1): 115-121. 10.1161/01.ATV.21.1.115
15. Wang YX, Martin-McNulty B, Huw LY, da Cunha V, Post J, Hinchman J, Vergona R, Sullivan ME, Dole W, Kauser K: Anti-atherosclerotic effect of simvastatin depends on the presence of apolipoprotein E. Atherosclerosis. 2002, 162 (1): 23-31.
16. Fukai T, Folz RJ, Landmesser U, Harrison DG: Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res. 2002, 55 (2): 239-249. 10.1016/S0008-6363(02)00328-0
17. Nespereira B, Perez-Ilzarbe M, Fernandez P, Fuentes AM, Paramo JA, Rodriguez JA: Vitamins C and E downregulate vascular VEGF and VEGFR-2 expression in apolipoprotein-E-deficient mice. Atherosclerosis. 2003, 171 (1): 67-73. 10.1016/j.atherosclerosis.2003.08.009
18. Gao M, Zhu S-Y, Tan C-B, Bei X, Zhang W-C, Guan-Hua D: Pinocembrin protects the neurovascular unit by reducing inflammation and extracellular proteolysis in MCAO rats. J Asian Nat Prod Res. 2010, 12 (5): 407-418. 10.1080/10286020.2010.485129
19. Liu R, Gao M, Yang ZH, Du GH: Pinocembrin protects rat brain against oxidation and apoptosis induced by ischemia-reperfusion both in vivo and in vitro. Brain Res. 2008, 1216: 104-115.
20. Zadelaar S, Kleemann R, Verschuren L, de Vries-Vander Weij J, van der Hoorn J, Princen HM, Kooistra T: Mouse placebos for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007, 27 (8): 1706-1721. 10.1161/ATVBAHA.107.142570
21. Wilson SH, Simari RD, Best PJ, Peterson TE, Lerman LO, Aviram M, Nath KA, Holmes DR, Lerman A: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol. 2001, 21 (1): 122-128. 10.1161/01.ATV.21.1.122
22. Maguire JJ, Wiley KE, Kuc RE, Stoneman VE, Bennett MR, Davenport AP: Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin. Exp Biol Med (Maywood). 2006, 231 (6): 806-812.
23. Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC: Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis. 2011, 10: 211- 10.1186/1476-511X-10-211
24. Blann AD, Belgore FM, Constans J, Conri C, Lip GY: Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol. 2001, 87 (10): 1160-1163. 10.1016/S0002-9149(01)01486-2
25. Wilson S, Herrmann J, Lerman LO, Holmes DR, Napoli C, Ritman EL, Lerman A: Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation. 2002, 105 (4): 415-418. 10.1161/hc0402.104119
26. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE: Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation. 1996, 93 (4): 672-682. 10.1161/01.CIR.93.4.672
27. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME: Simvastatin promotes atherosclerotic plaque stability in apoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol. 2002, 22 (11): 1832-1837. 10.1161/01.ATV.0000036081.01231.16